mFOLFOXIRI plus Bevacizumab
Phase 3Monoclonal antibody
mFOLFOXIRI plus Bevacizumab is one of 63 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1mFOLFOXIRI plus Bevacizumab
FFudan University
Phase 3
Eylea
RegeneronPreclinical
Emend IV
Merck & Co.Preclinical
PORTRAZZA
Eli LillyPreclinical
Gas-X
PPortuguese Oncology Institute, Coimbra
Preclinical
Ketalar
AAultman Health Foundation
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mFOLFOXIRI plus Bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- FFudan University